CV Therapeutics' angina drug fails trial

Investors cut the value of CV Therapeutics by 20 percent this morning after company officials announced that its angina drug Ranexa failed to demonstrate efficacy for patients with acute coronary syndrome. Ranexa was approved to treat chronic angina in patients who had not responded to other therapies. CV added that despite the trial failure it still expects to get an FDA approval for Ranexa as a first-line therapy. Analysts are also waiting to see how Ranexa performs as a therapy for diabetes.

- check out this press release
- read the report on the trial results from MarketWatch

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.